Logo image of XBIT

XBIOTECH INC (XBIT) Stock Fundamental Analysis

NASDAQ:XBIT - Nasdaq - CA98400H1029 - Common Stock - Currency: USD

3.05  +0.06 (+2.01%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to XBIT. XBIT was compared to 571 industry peers in the Biotechnology industry. While XBIT seems to be doing ok healthwise, there are quite some concerns on its profitability. XBIT is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year XBIT has reported negative net income.
In the past year XBIT has reported a negative cash flow from operations.
In the past 5 years XBIT reported 4 times negative net income.
In the past 5 years XBIT reported 4 times negative operating cash flow.
XBIT Yearly Net Income VS EBIT VS OCF VS FCFXBIT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M 400M 600M

1.2 Ratios

Looking at the Return On Assets, with a value of -16.24%, XBIT belongs to the top of the industry, outperforming 81.64% of the companies in the same industry.
Looking at the Return On Equity, with a value of -17.80%, XBIT belongs to the top of the industry, outperforming 87.52% of the companies in the same industry.
Industry RankSector Rank
ROA -16.24%
ROE -17.8%
ROIC N/A
ROA(3y)-10.18%
ROA(5y)9.63%
ROE(3y)-10.46%
ROE(5y)10.78%
ROIC(3y)N/A
ROIC(5y)N/A
XBIT Yearly ROA, ROE, ROICXBIT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50 -50

1.3 Margins

XBIT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
XBIT Yearly Profit, Operating, Gross MarginsXBIT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -200 -400 -600 -800

More info and screens

6

2. Health

2.1 Basic Checks

XBIT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for XBIT remains at a similar level compared to 1 year ago.
XBIT has less shares outstanding than it did 5 years ago.
XBIT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
XBIT Yearly Shares OutstandingXBIT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
XBIT Yearly Total Debt VS Total AssetsXBIT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M

2.2 Solvency

XBIT has an Altman-Z score of 2.72. This is not the best score and indicates that XBIT is in the grey zone with still only limited risk for bankruptcy at the moment.
XBIT has a better Altman-Z score (2.72) than 73.26% of its industry peers.
XBIT has a Debt/Equity ratio of 0.05. This is a healthy value indicating a solid balance between debt and equity.
XBIT has a Debt to Equity ratio of 0.05. This is in the lower half of the industry: XBIT underperforms 63.81% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Altman-Z 2.72
ROIC/WACCN/A
WACC9.51%
XBIT Yearly LT Debt VS Equity VS FCFXBIT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M 400M 600M

2.3 Liquidity

A Current Ratio of 11.13 indicates that XBIT has no problem at all paying its short term obligations.
XBIT's Current ratio of 11.13 is amongst the best of the industry. XBIT outperforms 82.71% of its industry peers.
XBIT has a Quick Ratio of 11.13. This indicates that XBIT is financially healthy and has no problem in meeting its short term obligations.
XBIT's Quick ratio of 11.13 is amongst the best of the industry. XBIT outperforms 82.71% of its industry peers.
Industry RankSector Rank
Current Ratio 11.13
Quick Ratio 11.13
XBIT Yearly Current Assets VS Current LiabilitesXBIT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for XBIT have decreased strongly by -20.82% in the last year.
The Revenue for XBIT has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)-20.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-47.26%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
XBIT Yearly Revenue VS EstimatesXBIT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
XBIT Yearly EPS VS EstimatesXBIT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 5 10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

XBIT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
XBIT Price Earnings VS Forward Price EarningsXBIT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
XBIT Per share dataXBIT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for XBIT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

XBIOTECH INC

NASDAQ:XBIT (2/24/2025, 3:18:02 PM)

3.05

+0.06 (+2.01%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)03-13 2025-03-13
Inst Owners15.8%
Inst Owner Change-94.68%
Ins Owners35.16%
Ins Owner Change0%
Market Cap92.96M
Analysts82.86
Price TargetN/A
Short Float %4.59%
Short Ratio12.12
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.47
P/tB 0.47
EV/EBITDA N/A
EPS(TTM)-1.15
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.8
FCFYN/A
OCF(TTM)-0.77
OCFYN/A
SpS0
BVpS6.45
TBVpS6.45
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -16.24%
ROE -17.8%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-10.18%
ROA(5y)9.63%
ROE(3y)-10.46%
ROE(5y)10.78%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 59.73%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.13
Quick Ratio 11.13
Altman-Z 2.72
F-Score2
WACC9.51%
ROIC/WACCN/A
Cap/Depr(3y)58.86%
Cap/Depr(5y)70.31%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-20.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-47.26%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-22.79%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-43.52%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-49.92%
OCF growth 3YN/A
OCF growth 5YN/A